my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
14-06-2012: Cytheris SA announced the appointment of Damian Marron as chief executive officer. Damian was previously CEO at Trophos SA.
Damian Marron, 49, is a highly experienced executive with strong experience in orphan diseases. He was previously CEO of Trophos SA from June 2008. Damian has extensive experience in the biotechnology and international pharmaceutical industry, including financing, corporate development, product and technology licensing, research and development and sales and marketing. Prior to Trophos, he was executive vice president corporate development at NicOx SA. Previously, he held various business development and operational roles at 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and Glaxo.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Cytheris SA announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for Cytheris’ CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML). This designation from ... more
Cytheris SA announced that the European Commission has granted an orphan designation for Cytheris' CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML). Additionally, Cytheris obtained scientific a ... more
Cytheris appoints Damian Marron as chief executive officer
Cytheris SA announced the appointment of Damian Marron as chief executive officer. Damian was previously CEO at Trophos SA. Damian Marron, 49, is a highly experienced executive with strong experience in orphan diseases. He was previously CEO of Trophos SA from June 2008. Damian has extensi ... more
Cytheris, Paris, is a product-oriented biopharmaceutical company focused on the research and development of new and critical agents for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial diseases ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
